Literature DB >> 21172382

Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010.

Maja Folkenberg1, Torbjörn Callréus, Henrik Svanström, Palle Valentiner-Branth, Anders Hviid.   

Abstract

Our study reviews the spontaneous reports of adverse events following immunisation submitted to the Danish Medicines Agency during the 2009-2010 influenza A/H1N1v season. During the study period (4 November 2009-31 March 2010), 607 reports comprising 1885 adverse events were reported among 339,507 influenza A/H1N1v vaccinated individuals (reporting rate, 179 per 100,000 vaccinated). The majority of individual case safety reports (85%) were submitted by physicians and other health care professionals and concerned known and non-serious reactions occurring within 1 day of vaccination (82%). Events of special interest as defined by EMA prior to vaccination campaign start, comprised 1% of all events. In conclusion, we did not observe any strong signals of any unknown or serious adverse events associated with influenza A/H1N1v vaccination in Denmark. Our experience also demonstrates the well-known limitations of spontaneous reports with respect to evaluation of a casual relationship and highlights the importance for a timely availability of background events rates and the need for new approaches to study late adverse effects following immunisation. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21172382     DOI: 10.1016/j.vaccine.2010.12.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.

Authors:  Agustín Ciapponi; Ariel Bardach; Agustina Mazzoni; Tomás Alconada; Steven A Anderson; Fernando J Argento; Jamile Ballivian; Karin Bok; Daniel Comandé; Emily Erbelding; Erin Goucher; Beate Kampmann; Ruth Karron; Flor M Munoz; María Carolina Palermo; Edward P K Parker; Federico Rodriguez Cairoli; Victoria Santa María; Andy S Stergachis; Gerald Voss; Xu Xiong; Natalia Zamora; Sabra Zaraa; Mabel Berrueta; Pierre M Buekens
Journal:  Vaccine       Date:  2021-08-13       Impact factor: 3.641

2.  Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes.

Authors:  Isla S Mackenzie; Thomas M MacDonald; Saad Shakir; Moira Dryburgh; Brian J Mantay; Patrick McDonnell; Deborah Layton
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

3.  Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review.

Authors:  Agustín Ciapponi; Ariel Bardach; Agustina Mazzoni; Tomás Alconada; Steven Anderson; Fernando J Argento; Jamile Ballivian; Karin Bok; Daniel Comandé; Emily Erbelding; Erin Goucher; Beate Kampmann; Ruth Karron; Flor M Munoz; María Carolina Palermo; Edward P K Parker; Federico Rodriguez Cairoli; María Victoria Santa; Andy Stergachis; Gerald Voss; Xu Xiong; Natalia Zamora; Sabra Zaraa; Mabel Berrueta; Pierre M Buekens
Journal:  medRxiv       Date:  2021-06-06

4.  Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.

Authors:  Thomas A Rasmussen; Martin R S Jørgensen; Stephanie Bjerrum; Søren Jensen-Fangel; Henrik Støvring; Lars Østergaard; Ole S Søgaard
Journal:  BMJ       Date:  2012-09-17

5.  Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study.

Authors:  F Rubinstein; P Micone; A Bonotti; V Wainer; A Schwarcz; F Augustovski; A Pichon Riviere; A Karolinski
Journal:  BMJ       Date:  2013-02-04

6.  The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.

Authors:  Hiroshi Yokomichi; Shintaro Kurihara; Tetsuji Yokoyama; Eisuke Inoue; Keiko Tanaka-Taya; Shigeru Kono; Zentaro Yamagata
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

Review 7.  Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines.

Authors:  Olivia Mahaux; Vincent Bauchau; Lionel Van Holle
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-25       Impact factor: 2.890

8.  Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.

Authors:  Simon de Lusignan; Gaël Dos Santos; Rachel Byford; Anne Schuind; Silvia Damaso; Vishvesh Shende; Chris McGee; Ivelina Yonova; Filipa Ferreira
Journal:  Adv Ther       Date:  2018-07-11       Impact factor: 3.845

9.  Why pandemic response is unique: powerful experts and hands-off political leaders.

Authors:  Erik Baekkeskov; Olivier Rubin
Journal:  Disaster Prev Manag       Date:  2014

Review 10.  Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review.

Authors:  Amit Bansal; Mai-Chi Trieu; Kristin G I Mohn; Rebecca Jane Cox
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.